New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra).
Cotter
Jill
J
Department of Family Medicine, University of Ottawa, Ottawa, Ont.
Wooltorton
Eric
E
D002170:Canada; D002318:Cardiovascular Diseases / Q000209:etiology*; D000068579:Celecoxib; D002986:Clinical Trials as Topic; D000075202:Contraindications; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D003657:Decision Making; D017277:Drug Approval; D006801:Humans; D007555:Isoxazoles; D011358:Product Surveillance, Postmarketing; D011720:Pyrazoles / Q000627:therapeutic use*; D012307:Risk Factors; D013449:Sulfonamides / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D000096926:Benzenesulfonamides
D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors; D007555:Isoxazoles; D011720:Pyrazoles; D013449:Sulfonamides; C406224:valdecoxib; D000096926:Benzenesulfonamides